Winston Pharmaceuticals, Inc.

OTC: WPHM · Healthcare · Medical - Pharmaceuticals

PublicHQ Vernon Hills, Reports USD

#831 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

——

FH —DQ —GM —SS 16

v0.1 · 5/100 weight · pillars only

↑ revenue growth (YoY), balance-sheet leverage · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

$1.4M

Rev growth YoY (TTM)

+98.0%

Net income (FY)

-$2.7M

Employees

Market cap

$7.7k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.4M$1.4M2009

Net income-$2.7M-$2.7M2009

Operating income-$2.7M-$2.7M2009

Total assets$1.7M$1.7M2009

Liabilities$1.2M$1.2M2009

Equity$488.6k$488.6k2009

Revenue trend

FY2005 – FY2009 · USD

FY05

FY06

FY07

$452.5k

FY08

$1.4M

FY09

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Winston Pharmaceuticals, Inc. booked $1.4M in FY2009 revenue, growing 208% year over year — faster than most Healthcare companies we track, at a -190.4% net margin.

Peers · Healthcare

Avivagen Inc.——Alternate Health Corp.——Biostax Corp.——Arrayit Corporation——

Key facts

CEOJoel E. Bernstein

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersVernon Hills, null

ExchangeOTC: WPHM

Employees9

IPO date2023-06-05

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.